This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases
Journal of Hematology & Oncology Open Access 25 January 2013
-
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium
Blood Cancer Journal Open Access 04 March 2011
-
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
Leukemia Open Access 29 April 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Verstovsek S, Silver RT, Cross NC, Tefferi A . JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia 2006; 20: 2067.
Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108: 346–352.
Ishii T, Bruno E, Hoffman R, Xu M . Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006; 108: 3128–3134.
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.
Lasho TL, Mesa R, Gilliland DG, Tefferi A . Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. Br J Haematol 2005; 130: 797–799.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472–3476.
Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139–4141.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pardanani, A., Lasho, T., Finke, C. et al. Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes. Leukemia 21, 2206–2207 (2007). https://doi.org/10.1038/sj.leu.2404749
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404749
This article is cited by
-
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone
Leukemia (2016)
-
An Immune Dysregulation in MPN
Current Hematologic Malignancy Reports (2014)
-
Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases
Journal of Hematology & Oncology (2013)
-
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium
Blood Cancer Journal (2011)
-
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
Leukemia (2010)